Cost and Healthcare Resource Implications of PARP Inhibitor Therapy for BRCA-Mutated Ovarian Cancer: A Systematic Literature Review
Author(s)
Somasundaram S, Phram. D, Anwesha A. Kandhare, M. Pharm, Santosh Kumar, MA.
SIRO Clinpharm, Mumbai, India.
SIRO Clinpharm, Mumbai, India.
OBJECTIVES: The objective of our systematic literature review was to assess the healthcare resource utilization and cost burden among BRCA-mutated ovarian cancer patients receiving PARP inhibitor therapy
METHODS: A search was conducted on PUBMED (Medline), EMBASE, Scopus, Web of Science, and Google Scholar to locate original studies describing the financial burden and healthcare resource utilization in patients with BRCA-mutated ovarian cancer treated with PARP inhibitors. Two impartial evaluators managed each stage of the evaluation process.
RESULTS: Consequently, a total of 17 pieces were chosen. The total monthly cost of the drugs varied between $10,000 and $14,000. Payers incurred typical monthly expenses ranging from $9,800 to $13,500, whilst patients contributed an average of $40 to $50. The average contribution from the financial aid programs ranged from $400 to $500. Additionally, olaparib, niraparib, and rucaparib were associated with increased rates of patient hospitalization and emergency department visits.
CONCLUSIONS: The projected price estimate for the treatment will remain elevated due to the prolonged duration of treatment, substantial drug costs, the requirement for ongoing supportive care, and continuous monitoring. Moreover, the escalation in the utilization of medical resources is attributed to the management of pharmacological side effects, including hematologic toxicity and gastrointestinal issues, necessitating frequent medical consultations and supportive therapies.
METHODS: A search was conducted on PUBMED (Medline), EMBASE, Scopus, Web of Science, and Google Scholar to locate original studies describing the financial burden and healthcare resource utilization in patients with BRCA-mutated ovarian cancer treated with PARP inhibitors. Two impartial evaluators managed each stage of the evaluation process.
RESULTS: Consequently, a total of 17 pieces were chosen. The total monthly cost of the drugs varied between $10,000 and $14,000. Payers incurred typical monthly expenses ranging from $9,800 to $13,500, whilst patients contributed an average of $40 to $50. The average contribution from the financial aid programs ranged from $400 to $500. Additionally, olaparib, niraparib, and rucaparib were associated with increased rates of patient hospitalization and emergency department visits.
CONCLUSIONS: The projected price estimate for the treatment will remain elevated due to the prolonged duration of treatment, substantial drug costs, the requirement for ongoing supportive care, and continuous monitoring. Moreover, the escalation in the utilization of medical resources is attributed to the management of pharmacological side effects, including hematologic toxicity and gastrointestinal issues, necessitating frequent medical consultations and supportive therapies.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE156
Topic
Clinical Outcomes, Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology